Logic Model and Impact Evaluation Methodology
The procurement contact named on the official notice.
The submission route named on the official notice.
The Catapult Centres are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth. (https://catapult.org.uk/catapult-centres/).
Our specific area is medicines discovery.
Part-funded by Innovate UK, an agency of the UK government, we are an independent not-for-profit company.
We bring together industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high-value products.
MDC is a national facility connecting the UK community to accelerate innovative drug discovery.
We provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.
By validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D.
MDC is currently in year 4 of our first 5-year grant funding agreement, referred to (GFA 1).
To support our GFA1 evaluation, we have a logic model outlining our theory of change, and a supporting evaluation methodology framework, which we are in the process of implementing.
In parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.
The estimated value is between £20,000.00 and £35,000.00.
Link to ITT documents here: https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545
What the supplier must deliver
We provide unique scientific capabilities and act
We provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.
By validating new ways of discovering medicines
By validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D.
To support our GFA1 evaluation, we have
To support our GFA1 evaluation, we have a logic model outlining our theory of change, and a supporting evaluation methodology framework, which we are in the process of implementing.
In parallel to the work we are
In parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.
Derived from the notice text — always confirm against the original documents.
Make the case to bid
Reveal who to approach at Medicines Discovery Catapult, and generate a go-to-market strategy from their news, accounts and people.
The full intelligence dossier
Our agent reads Medicines Discovery Catapult’s accounts, hunts live signals, finds the people who decide — and hands you a bid strategy plus a go-to-market influence plan, including what your team should post this week. You approve every paid step.
Ask me about this tender, the buyer, who wins their work, or whether you should bid.
- OCID
- ocds-h6vhtk-02c149
- Stage
- tender · Open
- Source
- Find a Tender
- Buyer ref
- 014806-2021
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Business Services
Medicines Discovery Catapult’s tender network
Assembling the network…